TAG:
laboratory director
New MoPath Lab Coalition Takes its Case to Congress
By Joseph Burns | From the Volume XX No. 8 – June 17, 2013 Issue
CEO SUMMARY: Prices recently established for molecular diagnostic tests are so low that they put patient access in jeopardy, declared a new lab industry coalition in a statement delivered to members of Congress. Called the Coalition to Strengthen the Future of Molecular Diagnosti…
Lab Test Utilization Delivers Big Gains at Cleveland Clinic
By Joseph Burns | From the Volume XXII NO. 8 – June 1, 2015 Issue
CEO SUMMARY: Since the launch of a laboratory test utilization program in 2011 at the Cleveland Clinic, more than 35,000 duplicate or inappropriate test orders have been stopped. The test utilization team introduced five initiatives that are not designed to cut spending but to in…
Fewer Blood Draws at UCSF Boost Patient Satisfaction
By Joseph Burns | From the Volume XXII NO. 7 – May 11, 2015 Issue
CEO SUMMARY: Physician residents at the UCSF School of Medicine set a target of reducing unnecessary blood draws. By eliminating needless needle sticks, the residents are focusing on patient experience while also encouraging physicians to pay more attention to the need to decreas…
Increasing Costs for Genetic Tests Are Busting Lab Budgets
By Joseph Burns | From the Volume XXII No. 6 – April 20, 2015 Issue
CEO SUMMARY: Across the nation, hospital administrators are recognizing that effective lab test utilization is a critical factor in a lab’s success. At Seattle Children’s Hospital, clinical pathologists, clinical chemists, and laboratory genetic counselors are …
February 17 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXII No. 3 – February 17, 2015 Issue
GeneCentric is a new lab testing company in Durham, North Carolina that was started by former executives of Laboratory Corporation of America. It intends to raise $20 million in a Series B capital offering. GeneCentric’s business model is to license molecular diagnostic tests, then develop the…
Attorneys Outline Issues in FDA’s LDT Guidance
By Joseph Burns | From the Volume XXI No.16 – November 24, 2014 Issue
CEO SUMMARY: Officials at the FDA believe that CLIA does not go far enough because it does not address the issues of whether laboratory-developed tests (LDTs) have been designed correctly or have been manufactured in accordance with sound standards. Also, CLIA does not include a process to verify…
Futurist Predicts Less Margin, More Consolidation in Market
By Joseph Burns | From the Volume XXI No. 9 – June 30, 2014 Issue
CEO SUMMARY: Based on interviews with 40 CEOs of major healthcare companies, one expert says that the next three years will bring major changes to healthcare. In his presentation at the Executive War College, Ted Schwab noted that these changes include a swift adoption of budgeted care (a…
Pathology Consolidation Underway in Washington
By R. Lewis Dark | From the Volume XXI No. 7 – May 19, 2014 Issue
CEO SUMMARY: Two regional pathology super-practices have emerged in Washington State. In each case, acquisitions and mergers are fueling the growth of the two large pathology groups. In Western Washington and the Seattle metro, CellNetix is the dominant pathology group, with 53 physicians…
New Skills Needed for Difficult Lab Job Market
By Joseph Burns | From the Volume XXI NO. 6 – April 28, 2014 Issue
CEO SUMMARY: Across the nation, a small but growing number of pathologists and lab directors has begun to engage career coaches and management recruiters specifically to sharpen their interviewing and career development skills, even though they are still employed. One expert says this tre…
CMS Gives Deemed Status to A2LA under CLIA Law
By Joseph Burns | From the Volume XXI No. 5 – April 7, 2014 Issue
CEO SUMMARY: Quietly published in the March 25 issue of the Federal Register was a notice that CMS had granted deeming authority for CLIA to the American Association for Laboratory Accreditation (A2LA). This action gives laboratories in the United States a new choice to meet the accredita…
CURRENT ISSUE
Volume XXXI, No. 5 – April 8, 2024
The fragmentation of consumer markets is reflected in clinical lab services, and The Dark Report examines this trend and how it will impact labs in the coming years. Also, The Dark Report notes that the FDA has issued a controversial memo to reclassify many high-risk IVD assays.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized